Key takeaways
Reyvow (lasmiditan) and Ajovy (fremanezumab) are both used to manage migraines, but they have different purposes and methods of administration. Reyvow (lasmiditan) is a serotonin agonist taken orally to treat migraines when they occur, while Ajovy (fremanezumab) is a CGRP receptor blocker injected under the skin to prevent migraines. Reyvow (lasmiditan) can relieve migraine pain within two hours but may cause dizziness and sleepiness, requiring you to avoid driving for at least eight hours after taking it. Ajovy (fremanezumab) is taken either once a month or once every three months and mainly causes injection-site reactions like pain and swelling. Reyvow (lasmiditan) is a controlled substance due to its potential for abuse, whereas Ajovy (fremanezumab) is not. Both medications are only available as brand-name options, and neither has been studied in children under 18 years old.
